Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Apr 26, 2021 (5 years ago)

Metoclopramide Injection USP

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Lack of Assurance of Sterility

Cause type: Sterility / contamination

A product that must be sterile could not be assured sterile, or was contaminated. A top reason for injectables, eye drops and IV products - loss of sterility assurance can lead to serious infections. All sterility / contamination recalls.

What was recalled

Metoclopramide Injection USP, 10 mg/2 mL (5 mg/mL), 2 mL Single-Use Vial, Rx Only, TEVA Parenteral Medicines, Inc. Irvine, CA 92618 NDC 0703-4502-04

Affected NDC 0703-4502-04

Compare with the code on your package — it is the most precise check available.

Drug: Metoclopramide

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Metoclopramide
NDC 00703-4502
HYDROCHLORIDE 5 mg/mL Injection, Solution
Intramuscular|intravenous
Teva Parenteral Medicines, Inc. Rx
Recalling firm
Teva Pharmaceuticals USA
NDC code
0703-4502-04
Origin
NJ, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0377-2021 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Metoclopramide recalls

See all
Class II · Moderate risk

Metoclopramide Injection USP

Lack of Assurance of Sterility: manufacturing areas for the recalled products exceeded acceptance levels for microbial recovery leading to a lack of sterility assurance for these sterile injectable products.

Terminated Sterility / contamination Teva Pharmaceuticals USA NDC 0703-4502-01 D-0277-2021
Class II · Moderate risk

Metoclopramide Oral Solution

CGMP Deviations: Purified water used to manufacture the drug products may have been contaminated with Burkholderia cepacia.

Terminated Microbial contamination VistaPharm, Inc. D-0459-2017

Other recalls by Teva Pharmaceuticals USA

All 2021 recalls